Ran Reshef, MD
Hematology · New York, NYNPI 1568659431
Payments from drug & device makers
Across 604 payments — averaging $8920.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$2.6M
- Gilead$1.7M
- Janssen Research & Development, LLC$410K
- Takeda Pharmaceuticals U.S.A., Inc.$300K
- Incyte Corporation$195K
- Genentech, Inc.$99K
- plus $116K from 18 others
Across 1 payment — averaging $108.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$109
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 32 | $2,561,195 |
| Gilead(2 entities) | 414 | $1,707,590 |
| Janssen Research & Development, LLC | 33 | $409,774 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $299,637 |
| Incyte Corporation | 32 | $194,879 |
| Genentech, Inc. | 14 | $98,939 |
| Pharmacyclics LLC, An Abbvie Company | 14 | $47,190 |
| National Marrow Donor Program | 4 | $22,031 |
| Shire North American Group Inc | 2 | $14,401 |
| Sanofi | 3 | $9,809 |
| Novartis | 7 | $6,776 |
| Johnson & Johnson | 4 | $6,023 |
| Sanofi-aventis U.S. LLC | 3 | $4,719 |
| Regeneron | 1 | $2,293 |
| Vertex | 2 | $613 |
| ZOLL Medical Corporation | 1 | $600 |
| Tersera Therapeutics LLC | 1 | $550 |
| Dr.reddy's Laboratories,inc. | 1 | $548 |
| Genentech USA, Inc. | 2 | $208 |
| Genetix Biotherapeutics Inc | 1 | $73 |
| AstraZeneca | 1 | $32 |
| AbbVie | 1 | $21 |
| Adaptive Biotechnologies Corporation | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
How this compares
$5,387,938 in reported general payments places this provider in the 95th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in New York
- Michael MauroNew York$34.9M
- Adam KittaiNew York$8.2M
- Barry CollerNew York$7.9M
- Divaya BhutaniNew York$4.8M
- Richard FurmanNew York$3.1M
- Joseph JurcicNew York$1.7M
- Marissa RybsteinNew York$1.6M
- Allyson OceanNew York$1.5M
- Mark HeaneyNew York$1.3M
- Jeffrey ZwickerNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.